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Objectives This study sought to evaluate the long-term outcomes after transcatheter aortic valve implantation (TAVI) in the Multicenter
Canadian Experience study, with special focus on the causes and predictors of late mortality and valve durability.
Background Very few data exist on the long-term outcomes associated with TAVI.
Methods This was a multicenter study including 339 patients considered to be nonoperable or at very high surgical risk
(mean age: 81  8 years; Society of Thoracic Surgeons score: 9.8  6.4%) who underwent TAVI with a balloon-
expandable Edwards valve (transfemoral: 48%, transapical: 52%). Follow-up was available in 99% of the pa-
tients, and serial echocardiographic exams were evaluated in a central echocardiography core laboratory.
Results At a mean follow-up of 42  15 months 188 patients (55.5%) had died. The causes of late death (152 patients)
were noncardiac (59.2%), cardiac (23.0%), and unknown (17.8%). The predictors of late mortality were chronic
obstructive pulmonary disease (hazard ratio [HR]: 2.18, 95% confidence interval [CI]: 1.53 to 3.11), chronic kid-
ney disease (HR: 1.08 for each decrease of 10 ml/min in estimated glomerular filtration rate, 95% CI: 1.01 to
1.19), chronic atrial fibrillation (HR: 1.44, 95% CI: 1.02 to 2.03), and frailty (HR: 1.52, 95% CI: 1.07 to 2.17). A
mild nonclinically significant decrease in valve area occurred at 2-year follow-up (p  0.01), but no further reduc-
tion in valve area was observed up to 4-year follow-up. No changes in residual aortic regurgitation and no cases
of structural valve failure were observed during the follow-up period.
Conclusions Approximately one-half of the patients who underwent TAVI because of a high or prohibitive surgical risk profile had
died at a mean follow-up of 3.5 years. Late mortality was due to noncardiac comorbidities in more than one-half of
patients. No clinically significant deterioration in valve function was observed throughout the follow-up period. (J Am
Coll Cardiol 2012;60:1864–75) © 2012 by the American College of Cardiology Foundation
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November 6, 2012:1864–75 TAVI and Long-Term OutcomesTranscatheter aortic valve implantation (TAVI) has
emerged as the treatment of choice in nonoperable patients
with severe symptomatic aortic stenosis and a good alterna-
tive to surgery in those considered to be at high surgical risk
(1–3). However, most data on TAVI are limited to acute and
1-year follow-up, and very few data exist on the outcomes
beyond 1-year follow-up (1). Several factors have been identi-
fied as predictors of poorer early and midterm (1 year) outcomes
after TAVI (4–7), but very few data exist on the factors
determining worse outcomes at longer-term follow-up.
Furthermore, the proper evaluation of transcatheter valve
durability at long-term follow-up is one of the most
important factors determining the potential expansion of
this technology toward younger and lower-risk patients.
Although TAVI is usually associated with excellent hemo-
dynamic results, few data exist on the long-term durability
of transcatheter valves (1,8–12). Importantly, the echocar-
diographic data available to date have been mainly obtained
from single center studies or multicenter registries without
central echocardiography core laboratory evaluation of the
echocardiographic findings. The lack of uniformity in echo-
cardiographic measurements might have introduced a bias
in the evaluation of transcatheter valve hemodynamic status,
including the degree and type of residual aortic regurgitation
(AR). Also, the number of patients evaluated at different
times over the follow-up period has tended to vary consid-
erably, and this precludes a real paired evaluation of the
echocardiographic exams, which in turn might lead to
somewhat misleading results on valve durability. The ob-
jectives of this study were to evaluate the long-term out-
comes after TAVI in the Multicenter Canadian experience
study, with special focus on the causes and predictors of late
mortality and valve durability.
Methods
The Canadian TAVI Multicenter experience study included
339 consecutive patients who underwent TAVI between
January 2005 and June 2009 in 6 Canadian centers with the
Cribier-Edwards (n  57), Edwards SAPIEN (n  275),
or SAPIEN XT (n  7) valve (Edwards Lifesciences, Inc.,
Irvine, California) in the setting of the Canadian compas-
sionate clinical use program approved by the Department of
Health and Welfare (Ottawa, Ontario, Canada). This
represented 61% of the patients evaluated by the Heart
Teams of the participating centers for a TAVI procedure
(the other 21% had surgical aortic valve replacement, and
18% had medical treatment). Patient and approach selection
as well as the main procedural characteristics and results
were detailed in a previous publication (4). Briefly, patients
considered eligible for TAVI underwent a systematic
workup protocol that included Doppler echocardiography,
coronary angiography, aorto-iliofemoral angiography, and
computed tomography. The patients were selected for
transfemoral (TF) or transapical (TA) approach, depending
on the size, disease, and degree of calcification of iliofemoralarteries. Starting in May 2007,
all cases were presented, dis-
cussed, and finally approved for
TAVI (TF or TA approach) in a
weekly conference call including
interventional cardiologists and
cardiac surgeons of participating
centers. Patient comorbidities
were defined with the Society of
Thoracic Surgeons risk score
definitions. Chronic pulmonary
obstructive disease (COPD) was
defined as the presence of forced
expired volume of air in 1 s
75% of predicted and/or the
use of chronic inhaled or oral
bronchodilator therapy. Chronic
kidney disease (CKD) was de-
fined as an estimated glomerular
filtration rate (eGFR) 60 ml/
min. Pulmonary hypertension (PH) was defined as a pul-
monary systolic pressure 60 mm Hg as estimated by
Doppler echocardiography or measured by cardiac catheter-
ization. Frailty was defined as a syndrome of decreased
reserve and resistance to stressors, resulting from multiple
declines across multiple physiologic systems leading to
vulnerability to adverse outcomes. No systematic tests were
performed for the evaluation of frailty, and patients were
considered nonoperable because of frailty mainly on the
basis of the criteria of the multidisciplinary team evaluating
them. Indeed, at least 2 cardiac surgeons had to agree when
frailty was the main criterion determining inoperability, and
the specific reasons for the decision had to be detailed
during a weekly conference call involving all centers partic-
ipating in the study. The study population was divided in 2
groups (i.e., early and late) depending on whether patients
had been treated in the first- or second-half of the TAVI
program experience in each participating center, to further
evaluate the potential influence of the learning curve on
clinical outcomes.
Clinical follow-up. Clinical follow-up was carried out in
clinical visits and/or through phone contact. The timing and
frequency of the clinical follow-up was determined by each
participating center. Most patients were followed at 1 year
after the procedure and annually thereafter. Follow-up data
were prospectively gathered in each participating center and
were available in all but 3 patients (99.1% of the study
population). Death and re-intervention at any time during
the follow-up period were recorded. If death occurred it was
further classified as of cardiac or noncardiac origin. The
complete medical file of the center taking care of the patient
was reviewed, and the primary care physician and cardiol-
ogist of the patient were consulted if any further informa-
tion was needed. Any sudden death was considered cardiac
unless proven otherwise. Any death occurring within the 30
Abbreviations
and Acronyms
AF  atrial fibrillation
AR  aortic regurgitation
CI  confidence interval
CKD  chronic kidney
disease
COPD  chronic pulmonary
obstructive disease
eGFR  estimated
glomerular filtration rate
HR  hazard ratio
PH  pulmonary
hypertension
TA  transapical
TAVI  transcatheter aortic
valve implantation
TF  transfemoraldays after the TAVI procedure was considered as cardiac.
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TAVI and Long-Term Outcomes November 6, 2012:1864–75Stroke was defined as a neurological deficit lasting24 h or
associated with brain lesions as determined by cerebral
imaging exams. Myocardial infarction was defined on the
basis of the guidelines for universal definition of myocardial
infarction (13).
Baseline and Procedural Characteristics of StudTable 1 Baseline and Procedural Characteri
Variables
All P
(n
Baseline
Age (yrs) 81
Male 152
Diabetes 79
Dyslipidemia 241
Hypertension 252
Current smokers 20
NYHA functional class
I–II 29
III–IV 308
Chronic atrial fibrillation 115
Coronary artery disease 234
Previous MI 173
Previous PCI 99
Prior coronary artery bypass grafting 116
Cerebrovascular disease 77
Peripheral vascular disease 120
COPD 100
eGFR 60 ml/min 119
STS score (%) 9.8
Porcelain aorta 61
Frailty 85
Pulmonary hypertension 84
Severe mitral regurgitation 27
LVEF (%) 55
Procedural and 30-day outcomes
Type of valve
Cribier-Edwards 61
Edwards SAPIEN 278
Experience
Early 169
Late 170
Successful procedure 322
Valve embolization 7
Need for second valve 9
Conversion to open heart surgery 6
Need for hemodynamic support 14
Annulus rupture 1
Major access site complications 45
Life threatening arrhythmias 28
MI 4
Stroke 8
Sepsis 10
Need for hemodialysis 9
Need for permanent pacemaker implantation 17
Death 36
Values are mean  SD or n (%). N  339.
BMI  body mass index; COPD  chronic obstructive pulmonary dejection fraction; MImyocardial infarction; NYHA New York Heart Associa
of Thoracic Surgeons Predicted Risk Of Mortality.Doppler-echocardiographic follow-up. Doppler echocar-
diography was systematically performed at baseline and at
hospital discharge in all patients. The timing and frequency
of echocardiographic exams at follow-up was determined by
each center, but most patients had an echocardiography at
pulationof Study Population
ts
)
Transfemoral
(n  162)
Transapical
(n  177) p Value
83 8 80 8 0.009
) 91 (56.1) 61 (34.5) 0.0001
) 37 (22.8) 42 (23.7) 0.898
) 104 (64.2) 137 (77.4) 0.020
) 102 (62.9) 150 (84.7) 0.0001
8 (4.9) 12 (6.8) 0.645
11 (6.8) 18 (10.2) 0.332
) 150 (92.5) 158 (89.3)
) 66 (40.9) 49 (27.8) 0.012
) 110 (67.9) 124 (70.0) 0.723
) 82 (50.6) 91 (51.4) 0.913
) 47 (29.2) 52 (29.6) 1.00
) 49 (30.3) 67 (37.9) 0.169
) 27 (16.8) 50 (28.4) 0.013
) 31 (19.3) 89 (50.3) 0.0001
) 45 (27.9) 55 (31.3) 0.551
124 85 113 81 0.232
9.0 5.8 10.5 6.9 0.034
) 28 (17.3) 33 (18.6) 0.779
) 42 (25.9) 43 (24.3) 0.802
) 35 (21.6) 49 (27.8) 0.256
18 (11.3) 9 (5.1) 0.045
55 14 56 14 0.721
) 46 (28.4) 15 (8.5) 0.0001
) 116 (71.6) 162 (91.5)
) 96 (59.3) 73 (41.2) 0.001
) 66 (40.7) 104 (58.8)
) 152 (93.8) 170 (96.1) 0.333
5 (3.1) 2 (1.1) 0.266
4 (2.4) 5 (2.8) 1.00
2 (1.2) 4 (2.3) 0.687
7 (4.2) 7 (3.9) 1.00
0 1 (0.6) 1.00
) 22 (13.9) 23 (13.0) 0.874
12 (7.4) 16 (9.0) 0.694
1 (0.6) 3 (1.7) 0.624
5 (3.0) 3 (1.7) 0.487
5 (3.0) 5 (2.8) 1.00
3 (1.8) 6 (3.4) 0.506
6 (3.6) 11 (6.2) 0.328
) 16 (9.9) 20 (11.3) 0.726
eGFR  estimated glomerular filtration rate; LVEF  left ventriculary Postics
atien
 339
 8
(44.8
(23.4
(71.1
(74.3
(5.9)
(8.6)
(90.9
(34.1
(69.0
(51.0
(29.4
(34.2
(22.9
(35.6
(29.7
 83
 6.4
(17.9
(25.1
(24.8
(8.1)
 14
(17.9
(82.0
(49.9
(50.2
(94.9
(2.0)
(2.6)
(1.7)
(4.1)
(0.3)
(93.3
(8.1)
(1.2)
(2.3)
(2.9)
(2.6)
(4.9)
(10.6
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tion; PCI percutaneous coronary intervention; STS-PROM Society
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November 6, 2012:1864–75 TAVI and Long-Term Outcomes1-year follow-up and then yearly. The echocardiographic
exams were analyzed at the Echocardiography Core Labo-
ratory of the Quebec Heart and Lung Institute (co-directed
by Drs. Philippe Pibarot and Jean G. Dumesnil) by expe-
rienced technicians blinded to clinical data and reviewed by
a cardiologist (Online Fig. 1). Transvalvular gradients and
alve effective orifice area measurements were performed
ollowing the methods previously described (14,15). The
everity of AR was evaluated with the multiparametric
pproach proposed in the American Society of Echocardi-
graphy/European Association of Echocardiography guide-
ines (16,17).
tatistical analyses. Qualitative variables were expressed as
ercentages and compared with the chi-square or Fischer
xact test. Quantitative variables were expressed as mean 
SD or median (25th to 75th interquartile range) and
compared with the Student t test or Wilcoxon rank sum
test, depending on variable distribution. A Cox multivariate
analysis including all variables with p value 0.10 in the
univariate analysis was used to determine the predictive
factors of cumulative late mortality and late (30 days)
mortality. Univariate and multivariate competing risks re-
gression analysis were used to determine the predictive
factors of cumulative cardiac mortality to account for non-
Causes of Death During Follow-Up PeriodTable 2 Causes of Death During Follow-Up Period
Cardiac 35 (23.0)
Cardiac failure 23 (15.1)
Sudden death 4 (2.6)
Myocardial infarction 6 (3.9)
Endocarditis 1 (0.7)
Post-mitral replacement 1 (0.7)
Noncardiac 90 (59.2)
Pulmonary failure 41 (26.9)
Kidney failure 12 (7.9)
Stroke 9 (5.9)
Major bleeding 7 (4.6)
Cancer 8 (5.3)
Other* 13 (8.6)
Unknown 27 (17.8)
Values n (%). N  152. *Caquexy: 2 (2.2%); multi-organ failure: 2 (2.2%); amyotrophic lateral
clerosis: 1 (1.1%); peripheral embolism: 1 (1.1%); pancreatitis: 1 (1.1%); bowel obstruction:
(1.1%); hip fracture: 1 (1.1%); cognitive decline: 2 (1.1%), vascular trauma: 1 (1.1%), diverticuli-
is: 1 (1.1%).
Univariate and Multivariate Predictors of CumulTable 3 Univariate and Multivariate Predict
Variables
Univariate
HR (95% CI)
Chronic atrial fibrillation 1.53 (1.14–2.06)
Cerebrovascular disease 1.32 (0.95–1.84)
COPD 1.72 (1.27–2.34)
eGFR 1.10 (1.01–1.21)*
Frailty 1.37 (0.99–1.88)
Pulmonary hypertension 1.54 (1.12–2.11)*For each decrease of 10 ml/min. N  339.
CI  confidence interval; COPD  chronic obstructive pulmonary disease;cardiac mortality. Survival curves up to 4 years were pre-
sented as Kaplan-Meier curves, and the log-rank test was
used for comparison between groups. An analysis of vari-
ance for repeated measures was performed to test for equal
means at different times (baseline, discharge, 12, 24, 36, and
48 months) for mean gradient and valve area values, and
post hoc comparisons were performed by Tukey-Kramer
procedure. A 2-way analysis of variance for repeated mea-
sures with interaction was used to compare the changes in
left ventricular (LV) diameters and LV ejection fraction
at different time points between groups (mild AR vs. no
or trace AR). Mixed effects ordinal regression was per-
formed to test for significant changes in AR over time.
The results were considered significant with p values
0.05. All analyses were conducted with the statistical
package SAS (version 9.2, SAS Institute, Inc., Cary, North
Carolina).
Results
The main baseline and procedural characteristics of the
study population are shown in Table 1.
Late outcomes. At a mean follow-up of 42  15 months,
a total of 188 patients (55.5%) had died, 36 patients (10.4%)
died within the 30 days after the TAVI procedure, and 152
patients (44.8%) died during the follow-up period. The
causes of death during the follow-up period are detailed in
Table 2. Of the 152 patients who died during the follow-up
period, 90 (59.2%) died because of noncardiac causes,
mostly because of pulmonary causes (45.6%) and end-stage
kidney disease (13.3%), and 35 patients (23.0%) died of
cardiac causes (cardiac failure in 15.1%). Re-intervention
was required in 2 patients who had valve endocarditis at 7
and 13 months after TAVI requiring transcatheter valve
explantation.
The predictors of mortality throughout the study period
on univariate and multivariate analyses are shown in Table 3.
In the multivariate analysis, the independent predictors of
cumulative late mortality were COPD (hazard ratio [HR]:
1.84, 95% confidence interval [CI]: 1.35 to 2.51, p 
0.0001), CKD (HR: 1.12 for each decrease of 10 ml/min in
eGFR, 95% CI: 1.02 to 1.23, p  0.024), chronic atrial
fibrillation (AF) (HR: 1.39, 95% CI: 1.03 to 1.89, p 
Late Mortalityf Cumulative Late Mortality
Multivariate Model
p Value HR (95% CI) p Value
0.005 1.39 (1.03–1.89) 0.031
0.098 — —
0.0004 1.84 (1.35–2.51) 0.0001
0.037 1.12 (1.02–1.23)* 0.024
0.052 1.41 (1.02–1.96) 0.034
0.007 — —ativeors oeGFR  estimated glomerular filtration rate; HR  hazard ratio.
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TAVI and Long-Term Outcomes November 6, 2012:1864–750.031), and frailty (HR: 1.41, 95% CI: 1.02 to 1.96, p 
0.034) . The predictors of cardiac death on univariate and
multivariate analyses are shown in Table 4. In the multi-
variate analysis, the predictors of cardiac mortality were
CKD (HR: 1.17 for each decrease of 10 ml/min in eGFR,
95% CI: 1.05 to 1.33, p  0.040) and PH (HR: 1.98, 95%
I: 1.19 to 3.27, p  0.008). There were no differences in
verall mortality or cardiac mortality between patients
reated in the early (first-half) and late (second-half) phase
f the study period (HR: 1.04, 95% CI: 0.77 to 1.40, p 
.82 for overall mortality; HR: 1.25, 95% CI: 0.78 to 2.07,
 0.36 for cardiac mortality). Also, the type of valve
(Cribier Edwards vs. Edwards SAPIEN, HR: 0.95, 95%
CI: 0.66 to 1.38, p  0.78 for overall mortality; HR: 1.48,
95% CI: 0.86 to 2.54, p 0.16 for cardiac mortality) had no
influence on clinical outcomes. To further analyze the
factors associated with late mortality (beyond the peri-
procedural period), the predictors of late mortality in those
patients who survived the TAVI procedure (no mortality
within the first 30 days) were analyzed on univariate and
multivariate analyses (Table 5). In the multivariate analysis,
the independent predictors of late mortality were COPD
(HR: 2.18, 95% CI: 1.53 to 3.11, p  0.0001), CKD (HR:
1.08 for each decrease of 10 ml/min in eGFR, 95% CI: 1.01
to 1.19, p  0.009), AF (HR: 1.44, 95% CI: 1.02 to 2.03,
p  0.044) and frailty (HR: 1.52, 95% CI: 1.07 to 2.17,
p  0.021).
The predictive factors of overall mortality in the TF and
TA groups are shown in Tables 6 and 7, respectively. A total
of 23 patients (6.8%) had a stroke during the study period,
8 patients within the first 30 days (2.4%), and 15 patients
(4.4%) during the follow-up period. All strokes were of
ischemic origin, and the antithrombotic treatment at the
Univariate and Multivariate Predictors of CumulTable 4 Univariate and Multivariate Predict
Univariate
HR (95% CI)
Cerebrovascular disease 1.57 (0.94–2.62)
Pulmonary hypertension 2.04 (1.26–3.32)
eGFR 1.15 (1.02–1.29)*
STS-PROM score 1.04 (1.01–1.07)
*For each decrease of 10 ml/min.
Abbreviations as in Tables 1 and 3.
Univariate and Multivariate Predictors of Late (>Table 5 Univariate and Multivariate Predict
Univariate
HR (95% CI)
Age (yrs) 1.02 (1.00–1.05)
Chronic atrial fibrillation 1.64 (1.19–2.28)
COPD 1.86 (1.33–2.61)
eGFR 1.08 (1.01–1.18)*
Frailty 1.58 (1.12–2.23)*For each decrease of 10 ml/min.
Abbreviations as in Table 3.time of stroke was aspirin  clopidogrel (n  9), aspirin
n  6), and warfarin (n  8).
The Kaplan-Meier survival curves up to 4-year follow-up
re shown in Figure 1.
oppler-echocardiographic data. After TAVI, the mean
ransvalvular gradient decreased to 10.5  4.1 mm Hg, and
ortic valve area increased up to 1.53  0.34 cm2 (p 
0.0001 vs. baseline for both). The changes in valve hemo-
dynamic status at 1-, 2-, 3-, and 4-year follow-up are shown
in Figure 2. A mild nonclinically significant decrease in
valve area was observed at 2-year follow-up (p 0.007), but
no further changes in valve hemodynamic status were
observed at 3- and 4-year follow-up (p  0.2). No cases of
tructural valve failure were observed throughout the study
eriod. Similar results were obtained when the analyses were
imited to the Edwards SAPIEN valve (n  180, n  107,
 58, and n  20 at 1-, 2-, 3-, and 4-year follow-up,
espectively) (p  0.006 for changes in mean gradient and
alve area at 2-year follow-up; p  0.3 for changes in mean
radient and valve area at 3- and 4-year follow-up) (Online
ig. 2). Some degree of AR after TAVI (hospital discharge)
ccurred in 70% of the patients and was mild or moderate in
0% and 10% of the patients, respectively. Residual AR was
aravalvular, transvalvular, and both paravalvular and trans-
alvular in 38%, 14%, and 48% of patients, respectively. The
hanges in residual AR over time are shown in Figure 3. No
ignificant changes (p  0.05) in the degree of residual AR
ere observed during the follow-up period and up to 3- and
-year follow-up. Similar results were obtained when the
nalysis was limited to the Edwards SAPIEN valve (p 
.05 for changes in residual AR over time) (Online Fig. 3).
he changes in LV end-diastolic diameters and LV ejection
raction over time were grouped according to the presence of
Cardiac Mortalityf Cumulative Cardiac Mortality
Multivariate Model
p Value HR (95% CI) p Value
0.084 — —
0.004 1.98 (1.19–3.27) 0.008
0.019 1.17 (1.05–1.33)* 0.040
0.013 — —
Days) Mortalityf Late (>30 Days) Mortality
Multivariate Model
Value HR (95% CI) p Value
.048 — —
.003 1.44 (1.02–2.03) 0.044
.0003 2.18 (1.53–3.11) 0.0001
.033 1.08 (1.01–1.19)* 0.009
.009 1.52 (1.07–2.17) 0.021ativeors o30ors o
p
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November 6, 2012:1864–75 TAVI and Long-Term Outcomesmild AR (vs. no or trivial AR) at hospital discharge (Fig. 4),
to further evaluate the potential deleterious effects of
mild residual AR. No significant changes in LV diame-
ters and LV ejection fraction were observed over time in
patients with mild AR, and no differences were detected
between these patients and those without AR or with
trace AR.
Functional capacity data. A significant improvement (p
0.0001) in the functional status of the patients as evaluated
by New York Heart Association functional class was ob-
served after the procedure, with 49.8%, 39.1%, 10.3%, and
0.8% of the patients in New York Heart Association
functional class I, II, III, and IV at last follow-up, respec-
tively (Online Fig. 4).
iscussion
he present study shows that approximately one-half of the
onoperable or high-surgical-risk patients who underwent
AVI with a balloon-expandable valve for the treatment of
evere symptomatic aortic stenosis had died at a median
ollow-up of 3.5 years. Most (4 of 5) patients died during
he follow-up period and, especially within the few months
fter the procedure, of noncardiac comorbidities. Chronic
ulmonary obstructive disease, CKD, frailty, and chronic
F were the main predictors of late mortality, whereas PH
nd CKD were the main factors associated with cardiovas-
ular mortality. A mild nonclinically significant decrease in
alve area and increase in gradient was observed 2 years after
AVI, but no further changes were observed up to 4-year
ollow-up as evaluated in a central echocardiography core
aboratory. The occurrence of mild residual AR, mostly
aravalvular, was frequent after TAVI but remained stable
Baseline Univariate and Multivariate Predictorsof Cumulative Late Mortality in TF Approa h PaTable 6 B seline Univariate and Multivariatof Cumulative Late Mortality in TF A
Variables
Univariate
HR (95% CI)
Chronic atrial fibrillation 1.68 (1.09–2.58)
Coronary artery disease 1.43 (0.90–2.26)
COPD 1.71 (1.09–2.70)
Pulmonary hypertension 1.81 (1.13–2.91)
N  162.
TF  transfemoral; other abbreviations as in Table 3.
Baseline Univariate and Multivariate PredictorsCumulative Late Mortality in P t ents with TA aTable 7 B seline Univariate and Mul ivariatCumulative Late Mortality in Patien
Variables
Univariate
HR (95% CI)
Male 1.44 (0.96–2.15)
Chronic atrial fibrillation 1.44 (0.94–2.18)
COPD 1.69 (1.12–2.54)
Frailty 1.73 (1.13–2.66)
eGFR 1.13 (1.01–1.29)*N  177. *For each decrease of 10 ml/min.
TA  transapical; other abbreviations as in Table 3.throughout the study period. Also, the presence of mild AR
had no deleterious consequences in LV diameter and
function up to 3-year follow-up. Transcatheter aortic valve
implantation was associated with a significant improvement
in patient functional status at follow-up.
Consistent with the results of this study, large multicenter
registries and the PARTNER (Placement of AoRTic
TraNscathetER Valve) trial have shown survival rates at
1-year follow-up after TAVI between 70% and 85%, with
most deaths occurring within the months after the proce-
dure (2,3,5,6). The recent U.K. multicenter registry showed
survival rates of 76% and 73% at 1- and 2-year follow-up,
respectively. However, the very low event rate after the first
year (3%) might be explained by the fact that only a
minority (one-third) of the study population was followed
up to 2 years (6). The mortality rate was 43.3% and 33.9%
at 2-year follow-up in the nonoperable and high-risk
cohorts of the PARTNER trial, respectively (10,11).
Buellesfeld et al. (8) reported a mortality rate of approxi-
mately 38% at 2-year follow-up after TAVI with the
self-expandable CoreValve system (Medtronic, Minneapo-
lis, Minnesota) in 125 patients, with a 2- to 3-fold increase
in all-cause mortality after the first 30 days, mostly in those
patients exhibiting a higher risk profile at baseline. Ussia et
al. (12) reported a mortality rate of 35% at 3-year follow-up
among 181 patients who had TAVI with the CoreValve
system. Gurvitch et al. (9) provided single-center data in 70
patients who underwent TAVI and had a minimum
follow-up of 3 years (median: 3.7 years). The survival rate at
3-year follow-up was 61%, and most patients died during
the follow-up period due to noncardiac comorbidities.
However, the relatively low number of patients included in
dictors
ach Patients
Multivariate Model
Value HR (95% CI) p Value
0.018 — —
0.098 — —
0.021 — —
0.014 1.63 (1.01–2.64) 0.043
chdictors of
th TA approach
Multivariate Model
p Value HR (95% CI) p Value
0.080 — —
0.092 — —
0.012 1.97 (1.29–3.01) 0.002
0.012 1.92 (1.23–2.99) 0.004
0.017 1.17 (1.02–1.35)* 0.021tientse Pre
ppro
pofpproae Pre
ts wi
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with poorer long-term outcomes.
Prognostic factors after TAVI. Several studies have iden-
tified baseline and procedural factors associated with acute
and 1- to 2-year follow-up mortality (4–7,10,11). The
present study identified COPD, CKD, frailty and chronic
AF as the main predictors of late mortality (beyond 1 year
and up to 6 years, mean of 3.5 years) after TAVI. Respira-
tory failure was the first cause of death during the follow-up
period, mainly due to respiratory infections leading to a
respiratory decompensation in patients with impaired pul-
monary function at baseline. Therefore, it is not surprising
that COPD appeared as the most important factor deter-
mining late mortality in this study. COPD is a well-known
risk factor of late mortality after surgical aortic valve
replacement (18), and previous TAVI studies had already
identified this factor as a predictor of acute and midterm
mortality (4,5,19). These results strongly suggest that an
Figure 1 Kaplan-Meier Survival Curves up to 4-Year Follow-Up
(A) Percentage of patients free of death up to 4-year follow-up. (B) Survival cu
cal [TA]). (C) Percentage of patients free of cardiac death up to 4-year follow-u
4-year follow-up.accurate evaluation of these patients by pulmonary special-ists before accepting them for a TAVI procedure might be
highly clinically relevant. Also, future studies will have to
better determine the factors associated with worse outcomes
among COPD patients undergoing TAVI and to imple-
ment measures to reduce acute exacerbations in this high-
risk group (20). Several studies have already identified
CKD as a major predictor of mortality after TAVI
(4 – 6,10,12,19). CKD is a marker of a higher cardiovascu-
lar and all-cause mortality in older people (21,22). The
presence of reduced eGFR levels determined a higher
mortality rate very early after the TAVI procedure, and this
continued throughout the entire study period. A closer
follow-up of such patients after the TAVI procedure might
be associated with an improvement in TAVI results. Frailty
is a very prevalent comorbidity among patients undergoing
TAVI today. This factor has been associated with poorer
outcomes in cardiovascular and noncardiovascular proce-
dures (23,24). The reasons why frailty was not found as a
p to 4-year follow-up, depending on the approach (transfemoral [TF], transapi-
Percentage of patients free of death, stroke, or myocardial infarction up torves u
p. (D)marker of worse outcomes after TAVI in previous studies
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been mainly subjective and not based on objective parame-
ters, and this could have introduced significant variability in
the evaluation of this factor between studies. Also, the
limited duration of the follow-up might have contributed to
the absence of relationship between frailty and poorer
outcomes in previous studies. Future studies will have to
establish objective parameters to obtain a more accurate
evaluation of this important factor and further determine its
prognostic value after TAVI. Chronic AF has been identi-
fied as a marker of poorer prognosis after cardiac surgery
(25). To the best of our knowledge, this is the first study
identifying chronic AF as a prognostic factor after TAVI.
Interestingly, most patients with chronic AF included in the
present study died of noncardiac causes. No increase in
stroke rate but a higher incidence of fatal bleeding was
observed in this group, partially explaining the greater
mortality among chronic AF patients. This highlights the
importance of an accurate control of the anticoagulation
therapy in these very old patients as well as of the avoidance
of combining multiple antithrombotic therapies. Late car-
Figure 2 Changes in Valve Hemodynamic Status Over Time
(A) Changes in mean gradient and valve area up to 1-year follow-up (from serial e
up to 2-year follow-up (from serial echocardiographic exams in 135 patients). (C)
graphic exams in 78 patients). (D) Changes in mean gradient and valve area up todiovascular mortality was mostly determined by PH andCKD. PH has been associated with a higher rate of
mortality after cardiac surgery (26), and previous TAVI
studies have identified PH as a marker of acute and midterm
mortality (4,6). PH makes the patient both more prone to
and more vulnerable in case of peri-procedural hemody-
namic complications. Also, the development of PH in the
setting of severe AS is a marker of an advanced stage of the
disease, and some of these patients will experience either
slight or no improvement after the procedure. In such
patients, especially those with very severe PH, a staged
procedure with balloon aortic valvuloplasty before TAVI for
both testing the hemodynamic response and improving
patient hemodynamic status might be useful to improve
patient selection and procedural results (27).
The analysis of the prognostic factors in each TAVI
approach group (TF or TA) showed that the variables
associated with poorer outcomes might vary according to
the approach. While PH was the main predictor of overall
mortality in the TF group, COPD and frailty were the most
important factors associated with late mortality in the TA
group. Future studies with a larger number of patients will
diographic exams in 218 patients). (B) Changes in mean gradient and valve area
s in mean gradient and valve area up to 3-year follow-up (from serial echocardio-
r follow-up (from serial echocardiographic exams in 22 patients).chocar
Change
4-yeahave to determine whether these differences are related to
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tics of the patients selected for each approach. Importantly,
the approach had no prognostic influence on acute or late
outcomes in this study.
Several studies have shown a significant improvement
in functional status and quality of life after TAVI
(2–12,28). The present study shows that the improve-
ment in functional class occurred in most patients after
the procedure and was maintained up to a median
follow-up of 3 years.
Valve durability. Several studies have evaluated transcath-
eter valve hemodynamic status up to 1-year follow-up,
showing valve function stability and no cases of structural
valve failure at midterm follow-up (2–11). Buellesfeld et al.
(8) and Ussia et al. (12) showed the absence of significant
changes in valve hemodynamic status up to 2- and 3-year
follow-up, respectively, after TAVI with the self-expandable
CoreValve system. The 2-year follow-up results of the
PARTNER trial showed the stability in valve hemodynamic
status after TAVI with the Edwards SAPIEN valve (10,11).
Gurvitch et al. (9) evaluated the valve hemodynamic status
after TAVI with a balloon-expandable Cribier-Edwards
Figure 3 Residual AR Over Time
(A) Changes in residual aortic regurgitation (AR) up to 1-year follow-up (from serial
follow-up (from serial echocardiographic exams in 135 patients). (C) Changes in r
(D) Changes in residual AR up to 4-year follow-up (from serial echocardiographic evalve up to 3-year follow-up, showing a mild nonclinicallysignificant increase and decrease in mean transvalvular
gradient and aortic valve area, respectively. However, none
of these studies except PARTNER evaluated the echocar-
diographic exams in a central echocardiography core labo-
ratory with standardized protocols, and in all studies the
number of patients being evaluated at each time period
changed (significantly decreased) over time, precluding a
real paired comparison of the echocardiographic measure-
ments at different times. These factors might have led to a
difficult or even misleading interpretation of the results with
regard to valve durability. The present study exclusively
evaluated patients with serial echocardiographic exams up to
4-year follow-up, therefore including the same patients and
number of exams at each time. The results showed good
stability of the Edwards balloon-expandable valve function
up to 4-year follow-up, with only mild nonclinically signif-
icant changes in transvalvular gradient and valve area at
2-year follow-up. No significant changes were observed over
time in the presence and degree of residual AR. Impor-
tantly, mild residual AR (mostly paravalvular) was frequent
after TAVI but had no impact on LV diameters and
function. These findings are in accordance with the results
ardiographic exams in 218 patients). (B) Changes in residual AR up to 2-year
l AR up to 3-year follow-up (from serial echocardiographic exams in 78 patients).
in 22 patients).echoc
esidua
xamsof previous surgical aortic valve replacement studies (29,30)
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feature after TAVI.
Study limitations. Although the data were prospectively
collected in each of the participating centers, there was no
pre-specified case report form designated for the purpose of
this study. However, that the cases were presented with a
similar presentation format in a weekly conference call
ensured data uniformity and partially compensated for this
Figure 4 Mild AR and Left Ventricular Changes Over Time
(A) Changes in left ventricular end diastolic diameter (LVd) and left ventricular eje
gitation (AR). (B) Changes in LVd and LVEF at 2-year follow-up, according to the pr
presence of mild AR.limitation. There was no independent event adjudicationcommittee for this study, but this might have been less
relevant, because the primary clinical outcome was the
occurrence of mortality (yes/no). Also, this was a multi-
center study, but the TAVI experience was very variable
among centers. The diagnosis of frailty was based on the
subjective evaluation of 2 cardiac surgeons. Although this
represents the most usual way of evaluating this comorbid-
ity, it might have introduced some variability in the diag-
raction (LVEF) at 1-year follow-up, according to the presence of mild aortic regur-
e of mild AR. (C) Changes in LVd and LVEF at 3-year follow-up, according to thection f
esencnosis, and further research is needed to obtain a more
Q
p
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criteria for echocardiographic evaluation (only echocardio-
graphic exams from patients with complete serial echocar-
diographic follow-ups were analyzed) led to a decrease in
the number of echocardiographic exams available for anal-
ysis. However, serial echocardiographic analysis was avail-
able in up to 90%, 67%, and 66% of the patients at risk at
1- , 2-, and 3-year follow-up, respectively. Also, the main
purpose of this study with respect to the echocardiographic
analysis was to evaluate in a central echocardiography core
laboratory the changes in valve hemodynamic status over time
to provide reliable data on valve durability. The number of
patients with serial echocardiographic exams up to 4-year
follow-up was limited, and future studies with a larger number
of patients are needed to confirm these results.
Conclusions
Although TAVI in patients considered to be nonoperable or
at very high surgical risk was associated with good hemo-
dynamic results translating into a significant functional
improvement in most patients, the mortality rate at a mean
follow-up 3.5 years after the procedure remained relatively
high (50%). Patients with COPD, CKD, frailty, and
chronic AF were at higher risk of death within the few years
after TAVI, suggesting that a more careful evaluation and
follow-up of patients with these comorbidities might trans-
late into better mid- to long-term outcomes. Also, cardiac
mortality was mostly related to the presence of PH and
CKD at the time of the TAVI procedure. The presence of
these entities, especially of PH, might reflect an overly
advanced cardiovascular disease condition, and the potential
role of staged procedures (balloon aortic valvuloplasty before
TAVI) in these patients might merit further evaluation.
Finally, the present results showing valve function stability
with only minor changes in valve hemodynamic status up to
4-year follow-up as evaluated in a central echocardiography
core laboratory provide important insights into the long-
term durability of balloon-expandable transcatheter valves.
Continuous monitoring of these patients beyond 4-year
follow-up is essential to provide definite data on long-term
transcatheter valve durability in the near future.
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